Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 134

Similar articles for PubMed (Select 22298186)

1.

Increased serum soluble CD147 levels in patients with systemic sclerosis: association with scleroderma renal crisis.

Yanaba K, Asano Y, Tada Y, Sugaya M, Kadono T, Hamaguchi Y, Sato S.

Clin Rheumatol. 2012 May;31(5):835-9. doi: 10.1007/s10067-012-1949-9.

PMID:
22298186
2.

Clinical significance of soluble CD31 in patients with systemic sclerosis (SSc): association with limited cutaneous SSc.

Sato S, Komura K, Hasegawa M, Fujimoto M, Takehara K.

J Rheumatol. 2001 Nov;28(11):2460-5.

PMID:
11708419
3.

Serum levels of tissue inhibitor of metalloproteinases 2 in patients with systemic sclerosis.

Yazawa N, Kikuchi K, Ihn H, Fujimoto M, Kubo M, Tamaki T, Tamaki K.

J Am Acad Dermatol. 2000 Jan;42(1 Pt 1):70-5.

PMID:
10607322
4.

Serum CCL23 levels are increased in patients with systemic sclerosis.

Yanaba K, Yoshizaki A, Muroi E, Ogawa F, Asano Y, Kadono T, Sato S.

Arch Dermatol Res. 2011 Jan;303(1):29-34. doi: 10.1007/s00403-010-1078-8. Epub 2010 Sep 8.

PMID:
20824279
5.

Serum IL-33 levels are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis.

Yanaba K, Yoshizaki A, Asano Y, Kadono T, Sato S.

Clin Rheumatol. 2011 Jun;30(6):825-30. doi: 10.1007/s10067-011-1686-5. Epub 2011 Jan 19.

PMID:
21246230
6.

A possible contribution of elevated serum clusterin levels to the inhibition of digital ulcers and pulmonary arterial hypertension in systemic sclerosis.

Yanaba K, Asano Y, Tada Y, Sugaya M, Kadono T, Sato S.

Arch Dermatol Res. 2012 Aug;304(6):459-63. doi: 10.1007/s00403-012-1219-3. Epub 2012 Feb 17.

PMID:
22350181
7.

Elevated circulating TWEAK levels in systemic sclerosis: association with lower frequency of pulmonary fibrosis.

Yanaba K, Yoshizaki A, Muroi E, Hara T, Ogawa F, Usui A, Hasegawa M, Fujimoto M, Takehara K, Sato S.

J Rheumatol. 2009 Aug;36(8):1657-62. doi: 10.3899/jrheum.081310. Epub 2009 Jun 16.

PMID:
19531747
8.

A clue for telangiectasis in systemic sclerosis: elevated serum soluble endoglin levels in patients with the limited cutaneous form of the disease.

Fujimoto M, Hasegawa M, Hamaguchi Y, Komura K, Matsushita T, Yanaba K, Kodera M, Takehara K, Sato S.

Dermatology. 2006;213(2):88-92.

PMID:
16902284
9.

Increased serum interleukin 23 in patients with systemic sclerosis.

Komura K, Fujimoto M, Hasegawa M, Ogawa F, Hara T, Muroi E, Takehara K, Sato S.

J Rheumatol. 2008 Jan;35(1):120-5. Epub 2007 Dec 15.

PMID:
18085738
10.

Augmented production of soluble CD93 in patients with systemic sclerosis and clinical association with severity of skin sclerosis.

Yanaba K, Asano Y, Noda S, Akamata K, Aozasa N, Taniguchi T, Takahashi T, Ichimura Y, Toyama T, Sumida H, Kuwano Y, Tada Y, Sugaya M, Kadono T, Sato S.

Br J Dermatol. 2012 Sep;167(3):542-7. doi: 10.1111/j.1365-2133.2012.11020.x. Epub 2012 Jul 19.

PMID:
22540233
11.

Serum CXCL16 concentrations correlate with the extent of skin sclerosis in patients with systemic sclerosis.

Yanaba K, Muroi E, Yoshizaki A, Hara T, Ogawa F, Shimizu K, Yozaki M, Hasegawa M, Fujimoto M, Takehara K, Sato S.

J Rheumatol. 2009 Sep;36(9):1917-23. doi: 10.3899/jrheum.090108. Epub 2009 Jul 15.

PMID:
19605674
12.

Elevated levels of circulating CD44 in patients with systemic sclerosis: association with a milder subset.

Komura K, Sato S, Fujimoto M, Hasegawa M, Takehara K.

Rheumatology (Oxford). 2002 Oct;41(10):1149-54.

13.

Serum levels of soluble vascular endothelial growth factor receptor-2 in patients with systemic sclerosis.

Jinnin M, Makino T, Kajihara I, Honda N, Makino K, Ogata A, Ihn H.

Br J Dermatol. 2010 Apr;162(4):751-8. doi: 10.1111/j.1365-2133.2009.09567.x. Epub 2009 Nov 3.

PMID:
19886888
14.

Clinical significance of circulating platelet-activating factor acetylhydrolase levels in systemic sclerosis.

Yanaba K, Asano Y, Tada Y, Sugaya M, Kadono T, Sato S.

Arch Dermatol Res. 2012 Apr;304(3):203-8. doi: 10.1007/s00403-011-1196-y. Epub 2011 Dec 3.

PMID:
22139405
15.
16.

Increased cutaneous T-cell-attracting chemokine levels in sera from patients with systemic sclerosis.

Hayakawa I, Hasegawa M, Matsushita T, Yanaba K, Kodera M, Komura K, Takehara K, Sato S.

Rheumatology (Oxford). 2005 Jul;44(7):873-8. Epub 2005 Mar 29.

17.

Type III procollagen N-terminal propeptide, soluble interleukin-2 receptor, and von Willebrand factor in systemic sclerosis.

Lee YJ, Shin KC, Kang SW, Lee EB, Kim HA, Song YW.

Clin Exp Rheumatol. 2001 Jan-Feb;19(1):69-74.

PMID:
11247328
18.

Serum levels of connective tissue growth factor are elevated in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis.

Sato S, Nagaoka T, Hasegawa M, Tamatani T, Nakanishi T, Takigawa M, Takehara K.

J Rheumatol. 2000 Jan;27(1):149-54.

PMID:
10648031
19.

Clinical significance of surfactant protein D as a serum marker for evaluating pulmonary fibrosis in patients with systemic sclerosis.

Asano Y, Ihn H, Yamane K, Yazawa N, Kubo M, Fujimoto M, Tamaki K.

Arthritis Rheum. 2001 Jun;44(6):1363-9.

20.

Clinical significance of serum growth differentiation factor-15 levels in systemic sclerosis: association with disease severity.

Yanaba K, Asano Y, Tada Y, Sugaya M, Kadono T, Sato S.

Mod Rheumatol. 2012 Sep;22(5):668-75. doi: 10.1007/s10165-011-0568-7. Epub 2011 Dec 9.

PMID:
22160844
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk